Global Heparin Market 2015-2019 - Key Vendors are Aspen, Leo Pharma, Pfizer & Sanofi-Aventis

News provided by

Research and Markets

30 Jun, 2015, 16:12 GMT

DUBLIN, June 24, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/f9k5fz/global_heparin) has announced the addition of the "Global Heparin Market 2015-2019" report to their offering.

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Heparin is an anticoagulant or blood thinner produced by basophils and mast cells. Though it has no effect on already formed clots, it enables the body's natural clot lysis mechanisms to function and dissolve clots. A porcine intestine or bovine lungs extract of heparin is used pharmaceutically in conditions such as DVT, pulmonary embolism, acute coronary syndrome, and atrial fibrillation to prevent clots. It is also used during surgeries to prevent clot formation.

The anti-inflammatory activity of heparin is a recent discovery. Heparin exhibits this trait through the neutralization of cationic mediators, inhibition of adhesion molecules, and the inhibition of heparanase, all of which are involved in leukocyte recruitment into tissues. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory agent.

According to the report, the growing prevalence of diseases is one of the key drivers of the market. Diseases such as coronary heart disease, kidney disorders, stroke, and inflammatory conditions are a result of blood clots, leading to a rise in the demand for heparin drugs.

Further, the report states that the patent expiry of top-selling drugs is a major challenge to vendors in the market, leading to the entry of generic drugs in the market and, consequently, a reduction in the price of branded drugs.

To calculate the market size, the report considers revenue generated from the sales of generic and branded therapeutic products, including

  • Unfractionated heparin (UFH)
  • Low molecular weight heparin (LMWH)
  • Ultra low molecular weight heparin (ULMWH)

Key Vendors

  • Aspen
  • Leo Pharma
  • Pfizer
  • Sanofi-Aventis

Other Prominent Vendors

  • Alchemia
  • Archimedes Pharma
  • Celgene
  • Dr. Reddy's
  • Eisai
  • Laboratorios Rovi Pharmaceuticals
  • Lee's Pharmaceutical
  • Menarini Group
  • Mylan
  • Sagent Pharmaceuticals
  • Fresenius Kabi
  • GlaxoSmithKline
  • Hospira
  • Sigma Tau
  • UCB

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Product Profiles
  6. Introduction
  7. Mechanism of Action
  8. Clinical Uses of Heparin
  9. Limitations of Heparin Use
  10. Suppliers of Crude Heparin
  11. Market Landscape
  12. Market Segmentation by Product Type
  13. Market Segmentation by Route of Administration
  14. Geographical Segmentation
  15. Buying Criteria
  16. Market Growth Drivers
  17. Drivers and Their Impact
  18. Market Challenges
  19. Impact of Drivers and Challenges
  20. Market Trends
  21. Trends and Their Impact
  22. Vendor Landscape
  23. Key Takeaways of Global Heparin Market
  24. Key Vendor Research

For more information visit http://www.researchandmarkets.com/research/f9k5fz/global_heparin

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com